Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2023	FY 2023
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-5.66	-0.37	-15.49	-21.38	-	-
Depreciation & Amortization	0.66	0.66	0.66	0.66	-	-
Stock-Based Compensation	0.32	0.16	0.81	1.35	-	-
Other Adjustments	2.96	-0.35	-2.26	0.01	-	-
Change in Receivables	-1.07	0.11	0.3	4.14	-	-
Changes in Accounts Payable	-0.84	-0.92	0.8	0.37	-	-
Changes in Accrued Expenses	1.76	1.49	0.28	0.14	-	-
Changes in Other Operating Activities	-0.35	-0.71	0.21	0.07	-	2.19
Operating Cash Flow	-2.36	0.08	-14.68	-14.64	-15.01	-5.65
Capital Expenditures	-	-	-	-	-0	-0
Sale of Property, Plant & Equipment	-	-	-	-	0.12	0.03
Purchases of Investments	-	-	-	-	-	-0.09
Proceeds from Sale of Investments	-	-	-	-	0.3	-
Other Investing Activities	-	-	-	-	0.01	0
Investing Cash Flow	-	-	-	-	0.43	-0.06
Long-Term Debt Repaid	-	-	-	-	-	-8.31
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-8.31
Issuance of Common Stock	17.92	1.53	15.11	3.86	18.74	32.56
Net Common Stock Issued (Repurchased)	17.92	1.53	15.11	3.86	18.74	32.56
Other Financing Activities	-	-	-	-	-0.12	-0.58
Financing Cash Flow	19.78	1.53	15.11	3.86	18.62	23.66
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.41	-0	0.08	-0.24	-	-
Net Cash Flow	17.83	1.6	0.5	-11.02	4.04	17.95
Free Cash Flow	-2.36	0.08	-14.68	-14.64	-15.01	-5.65
FCF Margin	-15.76%	0.49%	-	-	-8252.74%	-
Free Cash Flow Per Share	-0.91	0.05	-17.64	-0.01	-	-
Levered Free Cash Flow	-4.44	0.15	-13.53	-20.13	-15.01	-12.65
Unlevered Free Cash Flow	-2.09	0.02	-15.83	-20.59	-18.59	-7.4

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q